(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.17%) $82.49
(1.77%) $2.07
(-0.84%) $2 337.90
(-1.83%) $27.16
(-0.31%) $958.50
(0.21%) $0.934
(0.35%) $11.02
(0.17%) $0.797
(0.01%) $93.31
Live Chart Being Loaded With Signals
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...
Stats | |
---|---|
今日成交量 | 479.00 |
平均成交量 | 1 524.00 |
市值 | 9.94B |
Last Dividend | $0.324 ( 2023-06-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 14.96 |
ATR14 | $0 (0.00%) |
Ipsen S.A. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Ipsen S.A. 财务报表
Annual | 2023 |
营收: | $3.13B |
毛利润: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2023 |
营收: | $3.13B |
毛利润: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2022 |
营收: | $3.16B |
毛利润: | $2.63B (83.28 %) |
EPS: | $1.970 |
FY | 2021 |
营收: | $3.00B |
毛利润: | $2.46B (82.06 %) |
EPS: | $1.948 |
Financial Reports:
No articles found.
Ipsen S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.324 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.262 | 2013-06-11 |
Last Dividend | $0.324 | 2023-06-02 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-27 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $3.05 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.15 | |
Div. Directional Score | 9.82 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSMMY | Ex Dividend Junior | 2023-10-12 | Semi-Annually | 0 | 0.00% | |
ENGGY | Ex Dividend Knight | 2023-07-03 | Semi-Annually | 0 | 0.00% | |
UOVEY | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
KNRRY | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
CCOEF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
SBNC | Ex Dividend Junior | 2023-08-31 | Quarterly | 0 | 0.00% | |
FQVLF | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
ACCYY | Ex Dividend Knight | 2023-05-23 | Sporadic | 0 | 0.00% | |
XNGSY | Ex Dividend Junior | 2023-11-02 | Annually | 0 | 0.00% | |
MKKGY | Ex Dividend Knight | 2023-05-02 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.102 | 1.200 | 6.60 | 7.92 | [0 - 0.3] |
returnOnEquityTTM | 0.178 | 1.500 | 9.13 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.155 | -1.000 | 8.45 | -8.45 | [0 - 1] |
currentRatioTTM | 1.167 | 0.800 | 9.17 | 7.33 | [1 - 3] |
quickRatioTTM | 0.864 | 0.800 | 9.63 | 7.70 | [0.8 - 2.5] |
cashRatioTTM | 0.325 | 1.500 | 9.31 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0626 | -1.500 | 8.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.44 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 6.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.103 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.817 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.314 | 1.000 | 5.73 | 5.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.13 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.495 | 0.800 | -0.0358 | -0.0286 | [0.5 - 2] |
Total Score | 13.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.63 | 1.000 | 9.73 | 0 | [1 - 100] |
returnOnEquityTTM | 0.178 | 2.50 | 9.44 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 7.34 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.145 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.155 | 1.500 | 8.45 | -8.45 | [0 - 1] |
pegRatioTTM | 0.0973 | 1.500 | -2.68 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.270 | 1.000 | 5.76 | 0 | [0.1 - 0.5] |
Total Score | 6.15 |
Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。